This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) to Provide In-home Care With Primary Care Anywhere
by Zacks Equity Research
Humana (HUM) enhances its CenterWell brand with the launch of Primary Care Anywhere.
Why Humana (HUM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 HMO Stocks to Watch Amid Growing Premiums & Membership
by Debasmita Chatterjee
Expanding customer base, contract wins and a rapidly growing aging U.S. population will likely drive the performances of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry trends.
Humana (HUM) to Bring Enhanced Kidney Care to MA Members
by Zacks Equity Research
Humana (HUM) makes Interwell's extensive resources available to its MA members grappling with CKD and ESKD, and hence bring about better health outcomes for them.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Encompass Health's (EHC) Q2 Earnings Beat, '23 EPS View Raised
by Zacks Equity Research
Encompass Health's (EHC) Q2 results reflect a growing patient base and improved net patient revenue per discharge. Management anticipates 2023 adjusted EPS within $3.31-$3.53, up from the earlier view of $2.94-$3.23.
Company News for Aug 3, 2023
by Zacks Equity Research
Companies in The News Are: VRTX, DVN, AFL, HUM
Humana (HUM) Q2 Earnings Beat on Strong Individual MA Unit
by Zacks Equity Research
Humana's (HUM) Q2 results gain from strong pharmacy revenues and revenue growth within the Insurance segment, partly offset by higher benefits expenses.
Private Sector Jobs Come in Higher Than Expected
by Zacks Equity Research
Private Sector Jobs Come in Higher Than Expected.
ADP Jobs +324K Still Higher than Expected; CVS, KHC, HUM Report
by Mark Vickery
ADP Chief Economist Nela Richardson said, "The economy is doing better than expected... we continue to see a slowdown in pay growth without broad-based job loss."
Humana (HUM) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Humana (HUM) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 0.68% and 0.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?
by Zacks Equity Research
Humana's (HUM) second-quarter results are likely to reflect rising premiums and investment income.
5 Low-Leverage Stocks to Buy Following the Fed Rate Hike
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy HUM, TEX, ARI, ATO and TNK.
Centene (CNC) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 2.44% and 3.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) Q2 Earnings Beat on High Premiums, '23 View Raised
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results are aided by increased membership, and Medicaid and Medicare strength.
Humana (HUM) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $454.34, marking a +0.2% move from the previous day.
Here's What to Expect From Acadia Healthcare's (ACHC) Q2 Earnings
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q2 results are likely to reflect increased patient volumes across its U.S. operations, partly offset by a higher expense base.
Does Humana (HUM) Have the Potential to Rally 28.97% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 29% upside potential for Humana (HUM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will High Medical Costs Hurt Molina Healthcare's (MOH) Q2 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q2 results are likely to reflect the membership growth in its Medicaid and Medicare business units, partly offset by an elevated medical cost level.
Are Investors Undervaluing Humana (HUM) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Will High Tech Costs Hurt Teladoc Health (TDOC) in Q2 Earnings?
by Zacks Equity Research
Teladoc Health's (TDOC) Q2 results are likely to have benefited from improved access fees and growing BetterHelp membership, partly offset by elevated technology and development expenses.